In Depth 25 Mar 2019 Where Does Brexit Leave European Biotech? In the next couple of months, the UK will officially exit the EU, in a move that is popularly known as Brexit. With this date fast approaching, companies, organizations and individuals all over the world have speculated about how Brexit might impact them. According to the UK Prime Minister, Theresa May, at the launch of […] March 25, 2019 - 9 minutesmins - By Karen O’Hanlon Cohrt Share WhatsApp Twitter Linkedin Email
News and Trends 21 Mar 2019 Celgene and Exscientia Sign the Largest Deal in AI for Drug Discovery In a deal with €22M paid upfront and undisclosed “substantial milestones and royalties,” Exscientia will use its artificial intelligence technology to help Celgene speed up the discovery of drug candidates for cancer and autoimmune diseases. “It is the largest AI drug discovery deal done in the industry to date,” said Andrew Hopkins, CEO of Oxford-based […] March 21, 2019 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 18 Mar 2019 Shares Drop 40% as Allergy Therapeutics Announces Failed Phase III Trial Allergy Therapeutics has revealed that its immunotherapy for birch pollen allergy did not result in a significant symptom improvement when compared to a placebo. As a direct result of the announcement, the shares of Allergy Therapeutics on the London Stock Exchange dropped over 40% within two hours. The phase III trial enrolled 582 people across […] March 18, 2019 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 6 Mar 2019 Second Patient Achieves HIV Remission After Bone Marrow Transplant to Treat Cancer For the second time in history, an HIV-positive patient with blood cancer has achieved HIV remission following a customized bone marrow transplant to treat their cancer from an HIV-resistant donor. The HIV-positive patient received a bone marrow transplant to treat the blood cancer Hodgkin’s lymphoma, from which he also suffered. The researchers used this cancer […] March 6, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 27 Feb 2019 UK Biotech Gets Huge Grant to Launch Off-the-Shelf CAR-T Cancer Therapy to Clinic The UK biotech Cell Medica has received a €7.6M ($8.7M) grant from the Cancer Prevention and Research Institute of Texas to advance an off-the-shelf CAR-T cell therapy that can work not only in blood cancer but also in solid tumors. The funding will help the company to develop a special type of CAR-T cell therapy […] February 27, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Startup Scout 22 Feb 2019 This Biotech’s Algorithm Accelerates Cell Therapy Development Mogrify is the new kid on the block for cell therapy. Based in Cambridge, UK, it boasts technology that could speed up the development of cell therapies by predicting the best chemical recipe to transform mature adult cells into other cell types. Mission: To use next-generation sequencing and gene expression data to develop more cost-effective […] February 22, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 21 Feb 2019 First All-Inclusive Biotech Lab Facility Will Launch in Paris The young UK company RUNLABS plans to open the first facility where biotech companies can hire a package of lab space, lab services, offices, and even technicians. A common time sink in setting up a biotech company is the sheer amount of administration involved, such as hiring staff, getting insurance, and facilities maintenance. The company […] February 21, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 18 Feb 2019 Tuberculosis Treatment Kills Bacteria with Their Own Suicide Toxin A European academic research collaboration has found a new potential weapon against antibiotic-resistant tuberculosis: its own toxins. Many types of bacteria, such as the pathogen responsible for the deadly lung disease tuberculosis, Mycobacterium tuberculosis, use toxins to stay alive. For example, these toxins can be useful when the bacteria are starved or infected by viruses, […] February 18, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
More News! 6 Feb 2019 British Biotech Spin-Offs Get €40M Funding to Treat Narcolepsy Orexia and Inexia, two new virtual companies spun out of Sosei Heptares, will develop drugs for neurological diseases such as narcolepsy with funding from Medicxi Ventures. The companies will develop drugs that activate two molecules called OX1 and OX2. These molecules act as receptors of orexin, a protein that regulates arousal, wakefulness and sleep. The […] February 6, 2019 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
More News! 29 Jan 2019 Antibiotic Nasal Gel for Surgical Infections Cruises Through Phase I An antibiotic nasal gel, developed by the UK company Destiny Pharma to treat drug-resistant bacterial infections, has shown no adverse effects in healthy volunteers in a phase I trial. Destiny’s antibiotic nasal gel is designed to prevent post-surgical infections of the bacterial species Staphylococcus aureus, which can come in the dangerous drug-resistant strain MRSA. “About […] January 29, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 28 Jan 2019 New UK Policy Benefits Biotechs Waging War on Superbugs Among other measures, the new policy changes the way companies are reimbursed for antimicrobial drugs, which is expected to increase investment in biotech and the interest of big pharma in tackling antimicrobial resistance. Antimicrobial resistance is a huge problem. More and more pathogens are becoming resistant to antibiotics, as seen in the rising number of […] January 28, 2019 - 4 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Startup Scout 18 Jan 2019 This Biotech Turns Rejected Organs Into Drug Testing Models Engitix, a spinout from University College London, makes accurate disease models from human tissue that include the extracellular matrix from outside of the cells, an often overlooked but essential factor in the way cells behave inside our bodies. Mission: To make disease models in the lab that include the extracellular matrix, making them more […] January 18, 2019 - 4 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email